Get to know our clinical trials
Phase 1b/2 clinical trial to evaluate safety and efficacy of raludotatug deruxtecan, with or without other drugs in participants with high-grade serous epithelial ovarian carcinoma, primary peritoneal carcinoma or tubal carcinoma.
THE MAIN OBJECTIVE IS TO EVALUATE THE SAFETY AND TOLERABILITY OF RALUDOTATUG DERUXTECAN (R-DXD) ADMINISTERED IN COMBINATION WITH CARBOPLATIN IN PARTICIPANTS WITH RECURRENT HIGH-GRADE OVARIAN CARCINOMA.
Technical Summary
- PHASE 1B/2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RALUDOTATUG DERUXTECAN, WITH OR WITHOUT OTHER INVESTIGATIONAL ANTINEOPLASTIC DRUGS, IN PARTICIPANTS WITH HIGH-GRADE SEROUS EPITHELIAL OVARIAN CARCINOMA, PRIMARY PERITONEAL CARCINOMA, OR FALLOPIAN TUBE CARCINOMA WHO HAVE RELAPSED AFTER RECEIVING PLATINUM-DERIVED CHEMOTHERAPY.
- Code EudraCT: 2024-514674-47
- Protocol number: MK-5909-003
- Promoter: Merck Sharp & Dohme, S.A.
- Molecule/Drug: Raludotatug deruxtecán
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.